- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07679126
The Systemic Nature of Severe Traumatic Brain Injury (MANTRA)
The Systemic Nature of Severe Traumatic Brain Injury: Multi-Omic Analysis of Neural Trauma, Autoantibodies and the Gut-Brain Axis: The MANTRA Study
Studieoversikt
Status
Forhold
Detaljert beskrivelse
Severe traumatic brain injury (sTBI) is a devastating condition with no targeted therapies. Our pilot data in adolescents demonstrate that brain injury initiates an acute, strong immune response, marked by blood-brain barrier disruption and autoantibody formation, suggesting a novel avenue for therapeutic direction. Alterations in the gut-brain axis serve as a potential nidus of increasing immunogenicity and thus antibody formation. The major goal of this project is to define the immune mechanisms responsible for the interaction between brain injury and alterations in gut permeability via the gut-brain axis. Specifically, we will apply a novel multi-platform metabolomics approach, coupled with RNA sequencing, enabling identification of the mechanism responsible for early immune activation, secondary and tertiary brain injury, and neurodegeneration in adults with sTBI.
Current acute-management strategies remain largely focused on stabilizing cerebral physiology rather than addressing the molecular drivers of injury progression. The initial kinetic impact and subsequent secondary injury, such as neuroinflammation, neurotoxicity, and compromise of the blood brain barrier (BBB), potentiate a vigorous autoimmune response. Our pilot studies in adolescents demonstrated the activation of this strong immune response, marked by BBB disruption and autoantibody formation. This results in short and long-term inflammatory sequalae, including exacerbation of the initial injury, progression to chronic neurodegenerative diseases, and heightened disability and death.
Metabolomics comprehensively profiles (identifies and quantify) the small-molecule metabolites produced by cells, tissues, and microorganisms enabling the elucidation of metabolic pathways and their roles in addressing specific biological question. Although several omics studies have profiled time-resolved changes in adult and experimental models, no comparable work has been performed using multi-omics strategies in sTBI which remains essential. This represents a critical gap in our understanding of the developmental context of injury evolution. Lipids are essential for cellular functioning due to their pivotal roles in membrane composition, signaling, and energy metabolism, especially in the brain. Lipidomics, a subfamily of metabolomics, identifies and quantifies lips across cell types, organs, or full organisms. The investigation of cellular lipid pathways and networks provides critical insight into the molecular mechanisms underlying TBI. Emerging lipidomic studies show that circulating and CNS-derived lipid signatures correlate with injury severity, BBB breakdown, and long-term neurodegenerative risk thus making lipidomics essential in the comprehensive evaluation of sTBI pathogenesis.
The gut-brain axis, a bidirectional communication network between the gastrointestinal tract and central nervous system, has been identified in the pathophysiology of various forms of neurodegenerative disorders and recently implicated with TBI. Following sTBI, rapid alterations occur in gut motility, epithelial barrier integrity, immune signaling, and microbial community structure, collectively leading to gut dysbiosis and increased intestinal permeability. This is likely due to diffuse mucosal barrier dysfunction. In the gut, maintenance of mucosal integrity requires careful coordination between the epithelial lining and associated junctions, with immunologic contribution in regulating these relationships to alter permeability and absorption. The BBB, in contrast, carries a much greater degree of regulation and is relatively impermeable under normal physiological conditions, however, it is increased with brain injury thus permitting the influx of molecules that would not be present under normal conditions. These peripheral disturbances exacerbate neuroinflammation, oxidative stress, and neurodegeneration via the altered BBB. However, the precise mechanism by which this occurs has yet to be determined and remains a main objective of this study.
To discern the cells responsible for these alterations, scRNA-seq will be paired with global metabolomics, with an emphasis on detecting unique gut metabolites such as bacterial products and food antigens, not typically found in serum. scRNA will be used to identify circulatory cell type and clonal activation, integrated with metabolomics to specifically define the mechanism underlying the cytotoxicity of the gut permeability to the brain. This will be the first study to fully build a model examining the precise mechanism down to the cellular and molecular level with far-reaching impact. Ultimately, this may potentially identify targets for monoclonal deactivation and attenuation of secondary and tertiary brain injury.
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Ashley Franklyn
- Telefonnummer: 6163914051
- E-post: Ashley.Franklyn@corewellhealth.org
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- All patients must be between the ages of 18 to 65 at time of enrollment
- Study group cohort will consist of at least 20 patients admitted with severe TBI, defined as a GSC less than or equal to 8 with evidence of intracranial pathology on imaging.
- Trauma control cohort will include at least 10 patients matched on demographics and injury patterns without traumatic brain injury.
- Healthy control cohort will be comprised of 10 patients without acute traumatic injury or illness, matched to the sTBI patients based on demographics and medical comorbidities.
Exclusion Criteria:
- Pregnant Patients
- Prisoners
- Patients less than 18 years of age or greater than 65 years of age
- Patients with a penetrating brain injury mechanism, known neurodegenerative or psychiatric disorders, prior known traumatic brain injury, intracranial neoplasm, patients receiving massing transfusion or blood products prior to arrival, terminal illness or not expected to survive, confirmed or suspected brain death, known autoimmune or immunological condition, receiving immunosuppressant or immunomodulatory therapies, having a cardiac event leading to the injury, or for whom consent is unable to be obtained.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Study Group
The first cohort (Study Group) will consist of at least 20 patients admitted to CH Butterworth Hospital with a severe TBI, defined as a GCS ≤ 8 with evidence of intracranial pathology on imaging.
|
|
Trauma Control
The second cohort (Trauma Control) will include at least 10 patients matched on demographics and injury patterns without traumatic brain injury (head AIS 0).
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Systemic immune and metabolic responses after sTBI
Tidsramme: Time of injury and 1-month
|
Characterize the circulating cellular transcriptome using Bulk RNA-seq and single-cell RNA sequencing ScRNA-seq, compared to trauma and healthy controls to identify circulating cell types, clonal activity, and antibody formation that contribute to injury progression.
|
Time of injury and 1-month
|
|
Identifying the mechanisms of immune activation driving secondary injury
Tidsramme: 1 year
|
Define barrier disruption by performing both the 1H NMR and LC-MS metabolomic analysis (global, targeted, and lipidomics), transcriptomics, and proteomics to measure gut and blood-brain barrier permeability and markers of inflammation and neurodegeneration.
Pinpoint cell types, pathways, and antibody-mediated mechanisms contributing to progressive brain injury by integrating transcriptomic and metabolomic datasets.
|
1 year
|
|
Establishment of a biorepository for future biomarker discovery and data integration with the sTBI patient registry for long-term follow-up.
Tidsramme: 1 year
|
Bank stool and oral flora samples to study gut dysbiosis and investigate the link between gut microbiome and TBI and longitudinal downstream metabolic consequences leading neurodegeneration and psychiatric pathologies· Bank bronchoalveolar lavage (when available), and plasma for additional future ScRNA analyses at defined timepoints.
Establish longitudinal outcomes by leveraging a newly developed sTBI registry to follow patients over time, linking early immune and barrier changes with long-term risk of neurodegeneration.
|
1 year
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Elizabeth A Steensma, MD, FACS, Corewell Health West
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2026-1285
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .